Indian J Pharm Close
 

Figure 1: Efficacy of treatment as per Psoriasis Area Severity Index score in patients suffering from psoriasis. *P < 0.001 at 1st follow-up as compared to baseline in Group A, B and C. **P < 0.001 at 2nd follow-up as compared to baseline in Group A, B, and C. #P < 0.001 at 2nd follow-up as compared to 1st follow-up in Group B and C. @P < 0.05 at 2nd follow-up as compared to 1st follow-up in Group A. Group A (n = 52): (Topical treatment [Betamethasone valerate and Clobetasol propionate + salicylic acid]). Group B (n = 32): (Methotrexate + topical treatment [Betamethasone valerate and Clobetasol propionate + salicylic acid]). Group C (n = 30): (Cyclosporine + topical treatment [Betamethasone valerate and Clobetasol propionate + salicylic acid])

Figure 1: Efficacy of treatment as per Psoriasis Area Severity Index score in patients suffering from psoriasis. *<i>P</i> < 0.001 at 1<sup>st<?sup> follow-up as compared to baseline in Group A, B and C. **<i>P</i> < 0.001 at 2nd follow-up as compared to baseline in Group A, B, and C. #<i>P</i> < 0.001 at 2<sup>nd</sup> follow-up as compared to 1<sup>st</sup> follow-up in Group B and C. <sup>@</sup><i>P</i> < 0.05 at 2<sup>nd</sup> follow-up as compared to 1<sup>st</sup> follow-up in Group A. Group A (<i>n</i> = 52): (Topical treatment [Betamethasone valerate and Clobetasol propionate + salicylic acid]). Group B (<i>n</i> = 32): (Methotrexate + topical treatment [Betamethasone valerate and Clobetasol propionate + salicylic acid]). Group C (<i>n</i> = 30): (Cyclosporine + topical treatment [Betamethasone valerate and Clobetasol propionate + salicylic acid])